- Antibody-Drug Conjugate–Associated Ocular Toxicity: Mechanistic and Clinical Insights That Guide Toxicological Assessments
-
Room 304‚ Convention Center
Chair: Simon Kaja, Loyola University Chicago
Co-Chair: Cissy Li, HESI
Primary Endorser: Ocular Toxicology Specialty Section
Endorser(s): Drug Discovery Toxicology Specialty Section
Antibody-drug conjugates (ADCs) have become an increasingly important therapeutic modality in oncology, with expanding use across hematologic malignancies and solid tumors. With the growing number of approved ADCs, ocular adverse events have emerged as a recurring and sometimes dose-limiting toxicity. ADC-associated ocular findings include dry eye, conjunctivitis, keratitis, blurred vision, decreased visual acuity, microcyst-like epithelial changes, and, for selected agents or payload classes, concerns involving the posterior segment or optic nerve. These toxicities not only affect patient quality of life, but often necessitate treatment interruption, dose reduction, or discontinuation, thereby limiting optimal oncologic therapy. This session will provide an integrated drug development-focused perspective on the current understanding of the toxicology, ophthalmology, and pathology of ADC-associated ocular toxicity. The session will examine clinical phenotypes observed across ADC programs, mechanistic hypotheses underlying ocular toxicity, and current approaches for nonclinical and translational safety assessment. Presentations will address how ADC design features differentially contribute to ocular adverse findings and how ocular surface biology influences exposure and modifies risk. A key objective is to connect clinical observations with mechanistic and toxicological interpretation. Speakers and panelists will discuss the strengths and limitations of available nonclinical models, including animal studies, ocular histopathology, ophthalmic examinations, in vitro systems, and translational biomarkers. The session will also address practical challenges in clinical monitoring, grading of ocular adverse events, interpretation of ocular findings in toxicology studies, and development of mitigation strategies that preserve anticancer efficacy while reducing ocular risk. The session will consist of two focused scientific presentations followed by a moderated panel discussion. Panel participants will represent views from academia, the pharmaceutical industry, CROs, and the not-for-profit sector, providing a multidisciplinary forum to discuss current challenges, emerging mechanistic insights, and practical considerations for evaluating and mitigating ADC-associated ocular toxicity across the drug development continuum. By bringing together cross-functional expertise from these sectors, the session will provide attendees with an integrated framework for understanding, evaluating, and mitigating ADC-associated ocular toxicity.Session and Activity Type
Enter Note
Go to previous page in this tab
Event
